A decades-long scientific challenge in HIV vaccine development has been finding a way to train the immune system to produce antibodies that can target many variants of the virus. Traditional approaches haven’t worked — largely because HIV mutates rapidly and hides key parts of itself from the immune system.
Now, a new study combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply